In-depth analysis of the critical issues impacting the full spectrum of the pharmaceutical manufacturing value chain.
Following AbbVie's $63-billion acquisition of Allergan, which closed earlier this month (May 2020), the new AbbVie, reflecting the combined companies, has projected revenues of $50 billion. DCAT Value Chain Insights examines the key products, both...
Operation Warp Speed, a US government initiative to accelerate development of 14 promising vaccine candidates against COVID-19, was launched last week (May 15, 2020). What is behind the initiative, and how does it fit with other international...
European Union (EU) health ministers met this week (May 12, 2020) to begin discussing a pharmaceutical strategy for the EU, a move originally put forth in January of this year (2020), but which now will take into account the EU's economic recovery...
The Association for Accessible Medicines, which represents generic-drug and biosimilar manufacturers in the US, put forth a blueprint to facilitate a repatriation of pharma manufacturing to the US. What does the plan recommend?
A plan for...
Is the blockbuster model still in play or has the paradigm to more specialized drugs and smaller patient populations narrowed the blockbuster field? DCAT Value Chain Insights looks at which drugs, approved over the past several years, have...
The race is on to develop treatments and vaccines against COVID-19, and so is the need to assure supply of these potential drugs and vaccines. Pharma companies are leveraging their internal manufacturing networks but also partnering with...
Is drug development and the drug-review process slowing due to the novel coronavirus? What do new drug approvals and updates from the top pharmaceutical companies show?
Drug development and regulatory review
With the pharmaceutical industry, both...
Small molecules dominate recent new drug approvals, but how are they factoring in the recent or potential revenue gains of the top pharma companies? DCAT Value Chain Insights examines the winners and contenders among small-molecule drugs.
Small...
Vaccines, historically a commoditized sector, have risen to the top of the industry's watch list as the race for a vaccine against the novel coronavirus is on. What else is on DCAT Value Chain Insights' Top 10 Watch List for Biologics and...
Although a niche area, cell and gene therapies represent an active area of investment by CDMOs/CMOs to build manufacturing capabilities as well as having new CDMOs/CMOs enter this sector. Which companies are making the moves?
Building capabilities...
